Join Growin Stock Community!

Can-fite biopharma ltd.CANF.US Overview

US StockHealthcare
(No presentation for CANF)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

CANF AI Insights

CANF Overall Performance

CANF AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

CANF Recent Performance

-0.63%

Can-fite biopharma ltd.

0.05%

Avg of Sector

-0.31%

S&P500

CANF PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

CANF Key Information

CANF Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

CANF Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.

Price of CANF

CANF FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

CANF Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-9.19
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
11.10
PB Ratio
1.54
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-1095.53%
Revenue Growth (YoY)
7.35%
Profit Growth (YoY)
7.35%
3-Year Revenue Growth
-4.26%
3-Year Profit Growth
-4.26%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-9.19
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
11.10
PB Ratio
1.54
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-1095.53%
Revenue Growth (YoY)
7.35%
Profit Growth (YoY)
7.35%
3-Year Revenue Growth
-4.26%
3-Year Profit Growth
-4.26%

  • When is CANF's latest earnings report released?

    The most recent financial report for Can-fite biopharma ltd. (CANF) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating CANF's short-term business performance and financial health. For the latest updates on CANF's earnings releases, visit this page regularly.

  • How much debt does CANF have?

    As of the end of the reporting period, Can-fite biopharma ltd. (CANF) had total debt of 90K, with a debt ratio of 0.01. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does CANF have?

    At the end of the period, Can-fite biopharma ltd. (CANF) held Total Cash and Cash Equivalents of 6.45M, accounting for 0.84 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.